Patients with metastatic colorectal cancer previously treated with oxaliplatin were randomized to receive ZALTRAP or placebo in combination with the FOLFIRI regimen.
"We are excited by these results and are committed to bringing this novel therapy to patients as soon as possible," said Debasish Roychowdhury, M.D., Senior Vice President and Head, Sanofi Oncology. "We plan to submit regulatory applications for marketing approval to the U.S. Food and Drug Administration and the European Medicines Agency in the second half of the year."
Regeneron Pharmaceuticals has a potential upside of 12.5% based on a current price of $58.04 and an average consensus analyst price target of $65.3.
Regeneron Pharmaceuticals is currently above its 50-day moving average (MA) of $50.75 and above its 200-day of $35.63.
In the last five trading sessions, the 50-day MA has climbed 3.13% while the 200-day MA has risen 1.99%.
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.
No comments:
Post a Comment